This article is more than 5 years old. Information may no longer be current.

ThromboGenics reports 15.2 million euro loss in first half

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ThromboGenics reported a net loss of 15.2 million euros, or 0.42 euros per share, in the first half of 2017 compared with a net loss of 15 million euros, or 0.42 euros per share, in the first half of 2016, according to a press release.

Total revenues of 2.7 million euros were reported for the 6-month period, which included 1.9 million euros worth of product sales in the United States and 0.8 million euros in royalty income from U.S. sales of Jetrea (ocriplasmin). This compares with a net income of 4 million euros in 2016’s first half.

Research and development costs decreased from 12 million euros in 2016’s first half to 10.5 million euros this year.

The company reported cash and cash equivalents of 65.1 million euros as of June 30 compared with 80.1 million euros as of Dec. 31, 2016.